Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 901–999 of 999
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Paraná, R., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10796974/v1
Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception
Koca, N., Uyar, S., Şahintürk, Y., Yıldız, H., Prato, S. D., & DeFronzo, R. A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03346-2
From Guidelines to Clinical Practice: Expert Perspectives on Long‐Term Management of Obesity
Chen, H., Li, L., Zhang, J., Zhu, S., Cornier, M., & Purnell, J. Q. (2026) · Obesity · doi:10.1002/oby.70263
Semaglutide and resmetirom for MASH: the AASLD Practice Guidance tells us when, not which
Weglage, J., & Tacke, F. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.60
Therapie metabolischer Lebererkrankungen: Lebensstilintervention, Chirurgie und Pharmakotherapie
Huttasch, M., & KAHL, S. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01502-6
Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?
Flagiello, V., Barreby, E., Gentilucci, U. V., & Romeo, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70142
New therapeutic options for metabolic‐associated steatotic liver disease
Straatmijer, T., & Mulder, M. B. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70795
From adiposity to multisystem morbidity: the case for weight loss as disease modification
Sattar, N. A., Ferguson, L. D., & Lee, M. M. Y. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00186-5
Technology and Obesity: A Year in Review
Patra, S., Bhandarkar, A. P., Kapoor, N., & Kalra, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03775-1
Upcoming therapies for steatotic liver disease: Translating breakthroughs into clinical practice
Newsome, P. N., & Ajaz, S. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70143 · Cited by 2
Mahajan, N., Kaur, N., Sandhu, S. P. S., Patel, V., Boparai, H. K., Singh, K., & Singh, F. R. (2026) · Cureus · doi:10.7759/cureus.115501
Management of Obesity: Review of Adjunctive Therapies and Clinical Management Pearls
Sullivan, S. A., Tavakkoli, A., & Butsch, W. S. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.08.017
Swierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · npj Metabolic Health and Disease · doi:10.1038/s44324-026-00131-3
Takahashi, K., Yamada, N., Iwanaga, T., Sakuma, T., & Kamezaki, H. (2026) · Current Gastroenterology Reports · doi:10.1007/s11894-026-01055-0
Arbogast, M., Bayer, M., Biraima, M., Brunner, W., Rabl, C., Gerber, P., & Gerö, D. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100742
Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status
Kim, D. Y., Lee, K., Han, K. D., & Kim, B. K. (2026) · Biomedicines · doi:10.3390/biomedicines14091985
MASLD: cuando el hígado deja de ser el único protagonista
Restrepo, J. C. (2026) · Hepatología · doi:10.59093/27112330.176
Swamikkannu, D. M., Dasarapu, S., Mohan, K. D., & Shanmugam, A. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01199-7
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations
Pathan, F. K., & Williams, K. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.05
Glp-1 receptor agonists in obesity: Current evidence and clinical outcomes
Vidal, J. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.009
Passos, P. R. C., Filho, V. O. C., Moraes, B. D. F., Silveira, I. B., SÜFFERT, L. C., & Cançado, G. G. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.08.030
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Mansouri, E. S., de Queiroga, F. F., Barbosa, L., Azevedo, A. K., Donaldy, W., Mirbolouk, M. J., Freire, C. V. S., Rivera, A., Félix, I. F., Abreu, M., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.044249 · Cited by 1
Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
Cardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review
Enache, V., Popescu, D.-C., Marcu, B., Diaconu, M., & Nechita, A. C. (2026) · Medicina · doi:10.3390/medicina62091742
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Ramos, S. F., Fogelson, K. A., Muti, V. B., Aron, A. T., Salido, R. A., Richter, R. A., Mannochio-Russo, H., Hu, J., Hosseini, M., Loomba, R. S., et al. (2026) · mSystems · doi:10.1128/msystems.00720-26
Self-citationMironova, M., Ratziu, V., Rinella, M. E., Bansal, M. B., Noureddin, M., Alkhouri, N., Anstee, Q. M., Newsome, P. N., Schattenberg, J. M., Sanyal, A. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-340031
Self-citationPatel, D., Ewida, H. A., Tareq, S., Aziz, M. T., Chelikani, P. K., Bickel, U., & Ahmed, M. S. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00404
Abideen, Z. U., Waseem, M. H., Shoaib, A., Osama, M., Fatima, T., Panjwani, M. H., Ramzan, N., Thada, P. K., & Jalal, P. K. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003259
Crespo, J., Iruzubieta, P., de Vega, T., & Calleja, J. L. (2026) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2026.107536 · Cited by 1
Endocrine meets hepatic: the thyroid–liver axis in health and disease—an overview
Abdelsamad, H., & Mikosch, P. (2026) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-026-01180-5
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
El‐Kassas, M., Awad, A., AlNaamani, K. M., Alswat, K., & Elzouki, A.-N. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.57
Zhao, R., Zheng, J.-L., Wang, Y., Lu, B., Zhang, Y., & Deng, B.-C. (2026) · World Journal of Hepatology · doi:10.4254/wjh.124748
Targeting the cardiohepatic–metabolic axis: GLP‐1–based and incretin multi‐agonist therapies in MASH
Zhang, Y. W., & Hu, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70828
Patoulias, D., Muzurović, E. M., Rizzo, M., & Mantzoros, C. S. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109418
Duale und triagonistische Inkretine: Stand und Einfluss auf die MASLD
Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0
Combination pharmacotherapy for MASH: Potential synergistic approaches
Meije, D. A., Holleboom, A. G., & van de Graaf, S. F. J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118492
Weight management in cardiology practice: challenges and opportunities
Leening, M. J. G., Martens, F. M. A. C., & Hemels, M. E. W. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02075-1
Reichert, M., Strowitzki, M. J., Tuffs, C., Amati, A., Amin, D., Raj, S., Sprenger, T., Hecker, A., & Schneider, M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2927-4771 · Cited by 1
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716
The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology
Fernández‐Iglesias, A., Harris, E. N., Jalan‐Sakrikar, N., Kaur, S., Zapotoczny, B., Ikejima, K., & Gracia‐Sancho, J. (2026) · Hepatology · doi:10.1097/hep.0000000000001870 · Cited by 1
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
Sun, S.-P., Fang, Y., Liu, L., Li, Y., & Min, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1800909
Lipotoxicity in MAFLD/MASH: cellular mechanisms and targetable nodes
Tawai, J., Zhou, K., & Xiong, J. (2026) · Targetome · doi:10.48130/targetome-0026-0047
Modern methods for the diagnosis and management of obesity
Александровна, М. О., Валерьевна, Г. Е., Эдуардовна, Т. М., Martirosian, N. S., Кузина, И. А., Алексеевич, Т. А., Petunina, N. A., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-296
MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
Krzewiński, H., Wątroba, O., & Koza, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197540
Almujaidel, A., & Marzouk, E. (2026) · Nutrients · doi:10.3390/nu18193202
Ma, Z., Zhang, X., Leng, Y., & Chen, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1954630
Kotlyarov, S. N., Котлярова, А. А., Catanzaro, R., & Marotta, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198614
MASH and Chronic Viral Hepatitis: Pathophysiology, Diagnosis, and Management
Olaiya, V. O., Ejeheri, F. O., Osinuga, T. S., Ajayi, A. A., Okeke, C., Ajayi, A., Nwoye, V. T., Makinde-Ojo, S., Eze, M. C., Eze, A., et al. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02729-6
Merolla, A., & Rovere, P. Q. (2026) · Cardiac failure review · doi:10.15420/cfr.2026.22
Sex-stratified adipose-liver circuits in human MASLDPreprint
Koning, M., Hu, I. M., Kovynev, A., Landgraaf, R. G., Bahmani, A. H. A., Baars, D., Milutinović, D. V., Veličković, N. A., Franken, R. J., Acherman, Y. I. Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.24.754015
Boutari, C., Charalampidis, K., Sideras, L., Sinakos, E., & Goulis, I. (2026) · Life · doi:10.3390/life16101656
Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions
Hafez, A. H., Nour, M., Ibrahim, R., Othman, J., Mohamed, M. R., Awad, K., Zanco, J., Serra, V. D. S. B., Abdelnabi, M., Elbsiony, M., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02426-9
Kim, B., Kim, J., Kim, G., & Kim, K. (2026) · Pharmaceuticals · doi:10.3390/ph19101572
Ismaiel, A., & Dumitrascu, D. L. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102146
Endocrine determinants of MASLD: mechanisms and therapeutic targets
Chaturvedi, R., Mathew, A., Pradhan, A., Goyal, M., Sharma, M., Kachroo, V., Agrawal, C., Krishnamurthy, A., Atreja, S. M., & Atreja, A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1967494
Metabolische Dysfunktion-assoziierte steatotische Lebererkrankung (MASLD)
Rau, M., & Plauth, M. (2026) · De Gruyter eBooks · doi:10.1515/9783112213056-012
Review Article: Fibrosis‐4 Index in Steatotic Liver Disease—Past, Present and Future
Soni, K., Jahagirdar, V., ALBHAISI, O. A., Sterling, R. K., Arab, J. P., Blaney, H. L., & Díaz, L. A. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.71037
He, Y., Ma, T., 邢邯英, Cao, X., Song, F., Pan, Y., & Luping, R. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179418
Juárez-Hernández, E., Bautista-Mondragón, C. A., López-Pérez-Alférez, A., Castro‐Narro, G., & López-Méndez, I. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102153
Diagnosis and evaluation of obesity for therapeutic selection
Griebeler, M. L., Burguera, B. G., & Al-Husni, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.09.001
Emerging pharmacological treatment options for MASLD/MASH
Soto-Campillo, J., García-Rodríguez, M., & Chávez-Tapia, N. C. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.124
Ard, J. D., & Almandoz, J. P. (2026) · Obesity Reviews · doi:10.1111/obr.70228
Perumpail, B. J., Tou, A. M., & Panganiban, J. A. (2026) · JPGN Reports · doi:10.1002/jpr3.70246
Khalimov, Y. S., Владиславович, Е. М., Raikhelson, K. L., Bueverov, A. O., Dzgoeva, F. K., Насрединович, М. С., Обрезан, А. Г., Okovityi, S. V., Polyakova, E. A., Filippov, A. E., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-7114
DEMİR, E., Kayır, M., Abbasoglu, A., Ozkan, H., & Utku, İ. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15207876
Argano, C., Maggio, D., Pollicino, C., Cangialosi, V., Manno, S. B., Orlando, V., Monti, M. L., Grutta, A., Torres, A., & Corrao, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784959
Insulin resistance and hepatic steatosis
Tomović, A., Bakovic, N., Pantić, I., Baljosevic, N., Ranković, I., & Alempijevic, T. M. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102150
Syed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
The MASLD–Heart Axis: Biological Mechanisms, Cardiac Remodeling, and Clinical Implications
Oikonomou, E. K., Machairas, N. P., Theofilis, P., Louka, A. M., Xenou, M., Stampouloglou, P. K., Κατσαρού, Ο., Kokkinos, N. K., Lysandrou, A., Karamesinis-Spinthakis, S., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19101629
Ortiz‐Prado, E., Vasconez-Gonzalez, J., Izquierdo‐Condoy, J. S., & López-Jaramillo, P. A. (2026) · JMIR Public Health and Surveillance · doi:10.2196/99738
Reytor-González, C., Román-Galeano, N. M., Gavilanes, D. J., Rossetti, G., Cobellis, L., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100348
Kierzkowski, F., Skrzypek, W., Bryl, W., Paczkowska, A., & Hoffmann, K. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1977433
Nogueira, L. A. N. M., Balreira, I. C. T., Magalhães, K. D. B., Frota, L. B., Lemes, A. E. D. E. S., de Sousa, M. V. A., Gonçalves, L. D. S., Freitas, E. G. D., de Sousa, T. G. V., Amador, A. E., et al. (2026) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.66104/1xehbz24
Ferrarese, A., Vivian, L. M., Camillieri, G., Martino, L., Starnella, G., Arcari, M. P., Zampa, A. L., Burra, P., & Germani, G. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102471
The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO
Halpern, B., Baur, L. A., Blüher, M., Jackson-Morris, A. M., Ralston, J., & Ryan, D. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00234-2 · Cited by 1
Cai, H., Cai, H., Cai, T., Zhao, H., Wang, Q., Liu, C., Wu, W., & Cai, X. (2026) · Metabolites · doi:10.3390/metabo16100795
Therapie des Diabetes mellitus Typ 2
von Schwartzenberg, R. J., & Király, J. (2026) · Die Innere Medizin · doi:10.1007/s00108-026-02171-9
Hoffmann, K., Pucek, W. F., Skrzypek, W., Kierzkowski, F., Ratajczak, P., Maggio, V., Rizzo, M., El-Tanani, M., Rabbani, S. A., Bhongade, B. A., et al. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.17560
Wu, C., Zheng, Y., Fan, Y., Wang, J., Li, Y., Yuan, Y., Zhao, W., & Tang, Y. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108500
Self-citationFuture directions in obesity pharmacotherapy: Novel targets and pipeline therapies
Mauer, Y., & Isaacs, D. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.06.003
Amira, I., & Hasib, A. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101484
Pharmacotherapy for MASLD: current evidence and challenges in clinical practice
Pages, L., Rojo, D., Jiménez-Masip, A., Tricarico, E., Mas‐Carrió, E., Aguilar, A., Gómez, N., Molinero, L., & Pericas, J. M. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102477 · Cited by 1
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Cheng, P., Lu, C., Lin, C. L., Chiang, C., Yang, H., Kao, H., Wang, C., Chou, T.-J., Chang, M., Hsiao, T.-J., et al. (2026) · Liver International · doi:10.1111/liv.70926
Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective
Pereira, E. N. G. D. S., & Rodrigues, K. L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981916
A Bayesian decision framework for F1–F2 MASLD follow-up under adherence uncertainty
Boltyenkov, A., Eiswerth, M., Sanelli, P. C., Lazarus, J. V., WANG, J. J., Chen, W., Kao, S.-Y., Chalfin, D. B., Sangha, K., & Sanyal, A. J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1930169
Self-citationBurguera, B. G. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.09.002
Lauerer, J., Koschker, A., Rau, M., Geier, A., Germer, C., Faßnacht, M., Seyfried, F., & Kollmann, L. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08976-9
Zhu, G., Huang, Y., Huang, Y., & 杨文龙 (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1962068
Antifibrotic therapy in MASLD: fibrosis reversal and HCC prevention
Roeb, E., & Weiskirchen, R. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.90
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.